OptiMedica Names Alan Marquardt as New Vice President, Regulatory, Clinical and Quality
SANTA CLARA, Calif.-(Business Wire)-September 15, 2009 - Global ophthalmic company OptiMedica Corp. has appointed Alan Marquardt to the newly created position of vice president, regulatory, clinical and quality. Marquardt joins OptiMedica with more than two decades of equivalent senior management experience at several well-known medical device companies.
“Alan joins OptiMedica at a very busy and exciting time, as we continue to expand the clinical science supporting our PASCAL® Photocoagulator technology while also aggressively growing and diversifying our product portfolio,” said Mark J. Forchette, president and chief executive officer of OptiMedica. “His vast regulatory, clinical and quality affairs experience in both domestic and international medical device markets will be instrumental in helping us achieve significant and responsible growth with our current commercial portfolio, and his expertise will prepare us to participate in significant new ophthalmic segments in the future.”
Marquardt joins OptiMedica following a twenty-seven year career that included officer-level regulatory, clinical and quality affairs positions at companies including Sanarus Medical, Kyphon, Guidant Corp., UroQuest Medical Corporation, EP Technologies/Boston Scientific Corp., Schneider U.S. Stent/Pfizer and Medtronic. During this time, he developed expertise in the domestic and international management of pre- and post-market clinical trials, patient registries, pre-market and market approvals (PMA, 510(k) and CE Mark) as well as various quality initiatives including GMP (Good Manufacturing Practices), QSIT (Quality System Inspection Technique) and ISO 9000. Marquardt also has officer-level experience in corporate development and strategic planning.
“I believe there is an enormous opportunity at OptiMedica, as evidenced not only by the company’s revolutionary PASCAL platform technology, but also its very promising future technology and product pipeline, its experienced management team and its continuous commitment to scientific excellence,” said Marquardt. “This opportunity is what drew me to the company, and I look forward to being an instrumental part of its future success.”
About OptiMedica
Based in Santa Clara, Calif., OptiMedica Corp. is a global ophthalmic company dedicated to advancing the practice of ophthalmology for the benefit of physicians and their patients. The company holds the exclusive license to the PASCAL Photocoagulator technology, which was originally developed at Stanford University. Since its worldwide market introduction in 2006, PASCAL Photocoagulator technology has been used to treat more than 500,000 patients, representing more than 25 million patterns delivered. OptiMedica is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures and DAG Ventures. For more information, please visit www.optimedica.com.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
